Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for CAR and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for CAR and 80,000+ other tickers.
See exactly how CAR's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CAR and 80,000+ other tickers.
Avis Budget Group, Inc. is a prominent global provider of diverse mobility solutions, delivering vehicle rental services for both cars and trucks, alongside car-sharing options, to a broad clientele encompassing businesses and individual consumers. The company's brand portfolio includes Avis, which focuses on providing premium vehicle rentals and comprehensive mobility solutions to both commercial and leisure segments of the travel industry. For truck and cargo van rentals, the Budget Truck brand operates a fleet of approximately 20,000 vehicles. These are available for local and one-way hire…
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced initial results from the Company's Phase 1 study evaluating azercabtagene zapreleucel (azer-cel), an inves
On October 21, 2026, Avis Budget Group Inc (CAR) shares fell 4.0%, bringing the current price to $98.39. This price is down significantly from its 52-week high
CAR, USAS and APC have been added to the Zacks Rank #5 (Strong Sell) List on October 20, 2026.
First clinical evaluation of Xenetic's systemic DNase technology as an adjunct to CAR T-cell therapy in an investigator-initiated study conducted at Tel Aviv Sourasky University Medical Center Initial efficacy data expected in Q2 2027 FRAMINGHAM, MA / ACCESS Newswire / October 15, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its collaboration partner, PeriNess Ltd. ("PeriNess"), has informed the Company that the first patient has been dosed in an investigator-initiated clinical study evaluating systemic recombinant human DNase in combination with anti-CD19 CAR T-cell therapy in patients with large B-cell lymphoma ("LBCL") at the Tel Aviv Sourasky University Medical Center ("Ichilov Center") in Israel.
LB2501 is an off-the-shelf in vivo CAR-T therapy designed to generate dual-targeting CD19/CD20 CAR-T cells directly within the patient after a single infusion, making it the first known dual-targeting in vivo CAR-T therapy to receive FDA IND clearance IND clearance supports planned U.S. Phase 1/2 study and advances Legend Biotech's in vivo cell engineering platform BRIDGEWATER, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for LB2501, an investigational in vivo CAR-T therapy designed to generate CD19/CD20 dual-targeting chimeric antigen receptor T (CAR-T) cells directly within the patient, for the treatment of relapsed or refractory B-cell malignancies, including B-cell non-Hodgkin lymphoma.